O.E. Dahl

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial

Bengt I. Eriksson, O.E. Dahl, Nadia Rosencher et al. · Journal of Thrombosis and Haemostasis · 2007 · 984 citations · Full text

Medicine, Orthopaedic Surgery, Orthopedic Surgery +15

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial

Bengt I. Eriksson, O.E. Dahl, Harry R. Büller et al. · Journal of Thrombosis and Haemostasis · 2004 · 413 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Oral, direct Factor Xa inhibition with BAY 59‐7939 for the prevention of venous thromboembolism after total hip replacement

Bengt I. Eriksson, Lars C. Borris, O.E. Dahl et al. · Journal of Thrombosis and Haemostasis · 2005 · 300 citations · Full text

Medicine, Orthopedic Surgery, Pharmacology +17

Prolonged thromboprophylaxis following hip replacement surgery--results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin)

O.E. Dahl, G Andreassen, Trude Aspelin et al. · PubMed · 1997 · 265 citations

Medicine, Orthopaedic Surgery, Surgery +17

Frequency and timing of clinical venous thromboembolism after major joint surgery

B. T. Bjørnar̊, T. E. Gudmundsen, O.E. Dahl · Journal of Bone and Joint Surgery - British Volume · 2006 · 212 citations · Full text

Medicine, Orthopedic Surgery, Surgery +14